[1]祝亞軍.高危型HPV-DNA及TCT檢測篩查宮頸癌及宮頸癌前病變的價值[J].醫學信息,2019,(22):157-159.[doi:10.3969/j.issn.1006-1959.2019.22.054]
 ZHU Ya-jun.The Value of Screening High-Risk HPV-DNA and TCT for Cervical Carcinoma and Cervical Precancerous Lesions[J].Medical Information,2019,(22):157-159.[doi:10.3969/j.issn.1006-1959.2019.22.054]
點擊復制

高危型HPV-DNA及TCT檢測篩查宮頸癌及宮頸癌前病變的價值()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
157-159
欄目:
診療技術
出版日期:
2019-11-15

文章信息/Info

Title:
The Value of Screening High-Risk HPV-DNA and TCT for Cervical Carcinoma and Cervical Precancerous Lesions
文章編號:
1006-1959(2019)22-0157-03
作者:
祝亞軍
(鷹潭市婦幼保健院檢驗科,江西 鷹潭 335000)
Author(s):
ZHU Ya-jun
(Department of Clinical Laboratory,Yingtan Maternal and Child Health Hospital,Yingtan 335000,Jiangxi,China)
關鍵詞:
宮頸癌宮頸癌前病變HPV-DNATCT
Keywords:
Cervical carcinomaCervical precancerous lesionsHPV-DNATCT
分類號:
R737.33
DOI:
10.3969/j.issn.1006-1959.2019.22.054
文獻標志碼:
A
摘要:
目的 研究高危型人乳頭瘤病毒-DNA(HPV-DNA)及液基薄層細胞檢測系統(TCT)檢測篩查宮頸癌及宮頸癌前病變的價值。方法 選擇2016年3月~2019年2月本院收治的宮頸病變患者200例,所有患者均行高危型HPV-DNA檢測、TCT檢查,先行高危型HPV-DNA和TCT單項檢測,再行聯合檢測:T1(先高危型HPV-DNA,再TCT)、T2(先TCT,再高危型HPV-DNA)。隨訪記錄其病理檢查結果,以病理檢查結果為“金標準”,評估各檢測方法的敏感性、特異性、準確度。結果 本研究中經組織病理學檢查證實陰性168例(慢性宮頸炎),陽性32例(CINⅠ級及以上),其中CINⅠ16例,CINⅡ~Ⅲ15例,浸潤性癌1例;高危型HPV-DNA檢測宮頸癌前病變及宮頸癌的敏感性高于TCT、T2,特異性、準確度低于TCT、T2、T1,差異有統計學意義(P<0.05);T1診斷宮頸癌及宮頸癌前病變的特異性、準確度均高于高危型HPV-DNA、TCT,差異有統計學意義(P<0.05);T1準確度、敏感性均高于T2,差異有統計學意義(P<0.05)。結論 高危型HPV-DNA及TCT檢測在篩查宮頸癌及宮頸癌前病變方面各具優勢,而先行高危型HPV-DNA檢測再行TCT檢測篩選價值更高。
Abstract:
Objective To study the value of high-risk human papillomavirus-DNA (HPV-DNA) and liquid-based thin-layer cell detection system (TCT) in screening cervical carcinoma and cervical precancerous lesions. Methods 200 patients with cervical lesions admitted to our hospital from March 2016 to February 2019 were selected. All patients underwent high-risk HPV-DNA testing and TCT testing. The high-risk HPV-DNA and TCT single-test were performed first, followed by joint testing: T1 (first high-risk HPV-DNA, then TCT), T2 (first TCT, then high-risk HPV-DNA). The pathological examination results were followed up, and the pathological examination results were regarded as "gold standard". The sensitivity, specificity and accuracy of each detection method were evaluated. Results In this study, 168 cases (chronic cervicitis) and 32 cases (CINI grade and above) were confirmed by histopathological examination, including 16 cases of CINI, 15 cases of CINII~III, and 1 case of invasive carcinoma. High-risk HPV-DNA detection the sensitivity of cervical precancerous lesions and cervical carcinoma was higher than that of TCT and T2. The specificity and accuracy were lower than TCT, T2 and T1,the difference was statistically significant (P<0.05). T1 diagnosis of cervical cancer and cervical precancerous lesions the specificity and accuracy were higher than those of high-risk HPV-DNA and TCT,the difference was statistically significant (P<0.05). The accuracy and sensitivity of T1 were higher than T2,the difference was statistically significant (P<0.05).Conclusion The high-risk HPV-DNA and TCT tests have advantages in screening cervical carcinoma and cervical precancerous lesions, and the high-risk HPV-DNA test has a higher value for TCT detection.

參考文獻/References:

[1]師曉艷,雷俠.宮頸液基細胞學檢查與高危型HPV檢測用于宮頸癌前病變并發感染早期篩查的對比研究[J].中國性科學,2017,26(1):33-35. [2]朱琳.TCT、HPV-DNA分型聯合陰道鏡檢測在宮頸病變篩查中的作用[J].中國婦幼保健,2017,32(14):3375-3378. [3]鄭蓓佳,陳琪,顧華敏.高危型人乳頭狀瘤病毒聯合TCT檢測在宮頸癌早期篩查中的應用[J].中國衛生檢驗雜志,2016,26(2):247-249. [4]任士霞,李連芹.高危型HPV檢測與TCT篩查宮頸癌準確性比較[J].齊魯醫學雜志,2017,32(6):669-672. [5]王登海,陳忠萍,居峰,等.TCT聯合HPV-DNA及端粒酶檢測在宮頸癌前病變評估中的應用價值[J].檢驗醫學與臨床,2017,14(21):65-66. [6]喻垚,郭變琴,羅光麗,等.液基細胞學與高危型HPV-DNA聯合檢測在宮頸病變篩查中的意義[J].檢驗醫學與臨床,2015, 12(11):1550-1551. [7]帕提曼·米吉提,唐努爾·阿不力米提,古扎麗努爾·阿不力孜.高危型HPV檢測聯合TCT用于宮頸癌篩查及其危險因素分析[J].中國地方病防治雜志,2016,31(5):577. [8]高華玲,尹德娥,杜杰,等.TCT和HR-HPV-DNA檢測在宮頸癌和癌前病變篩查中的臨床價值[J].標記免疫分析與臨床,2017,24(10):1115-1118. [9]陶志梅,潘敏,俞美娟,等.高危型人乳頭瘤病毒感染聯合液基薄層細胞檢測對宮頸癌及宮頸癌前病變篩查與隨訪的臨床意義[J].中華醫院感染學雜志,2017,27(10):2340-2343. [10]熊煒,陳萰.TCT和HPV-DNA聯合檢測在宮頸癌及癌前病變篩查中的應用價值[J].中國計劃生育和婦產科,2015,7(12):45-47.

相似文獻/References:

[1]廖加群,曹 雪,陳燕平,等.宮頸癌盆腔淋巴結轉移分布及危險因素分析[J].醫學信息,2018,(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
 LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Medical Information,2018,(22):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]徐 潔.宮頸癌篩查及預防的研究進展[J].醫學信息,2018,(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
 XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Medical Information,2018,(22):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[3]黃 花,徐冬冬,章麗霞.TGF-β1在宮頸癌中的研究進展[J].醫學信息,2018,(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
 HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Medical Information,2018,(22):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[4]夏易曼娜,李虎成.腹腔鏡下宮頸癌根治術與傳統開腹手術的對比研究[J].醫學信息,2018,(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
 XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Medical Information,2018,(22):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[5]楊 軍,王翠平,李 龍,等.義安區體檢HPV-DNA篩查結果分析[J].醫學信息,2018,(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
 YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Medical Information,2018,(22):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[6]王雙英,張 娜,劉 芳.具有高危復發因素的早期宮頸癌術后輔助治療進展[J].醫學信息,2018,(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
 WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Medical Information,2018,(22):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
[7]聶小鳳,翟慧慧,冷天艷,等.宮頸脫落細胞miR34a檢測在HR-HPV陽性患者 分流中的作用分析[J].醫學信息,2018,(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
 NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Medical Information,2018,(22):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[8]吳曉玲,周桂華.miR-187在宮頸癌中的表達與臨床病理關系的研究[J].醫學信息,2018,(16):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
 WU Xiao-ling,ZHOU Gui-hua.Expression of miR-187 in Cervical Cancer and Its Relationship with Clinicopathological Features[J].Medical Information,2018,(22):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
[9]夏為書,彭莉貞,鐘清玲.我國宮頸癌患者配偶生活質量評價的研究現狀[J].醫學信息,2018,(23):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
 XIA Wei-shu,PENG Li-zhen,ZHONG Qing-ling.Research Status of Spouse Quality of Life Evaluation of Cervical Cancer Patients in China[J].Medical Information,2018,(22):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
[10]邢 均.全身麻醉聯合硬膜外麻醉在宮頸癌手術中的應用及效果評價[J].醫學信息,2019,(01):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]
 XING Jun.Application and Evaluation of General Anesthesia Combined with Epidural Anesthesia in[J].Medical Information,2019,(22):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩